In this discussion, Dr. Jeff Yu explores the topic of atopic dermatitis treatment news and the upcoming decision by the FDA on tapinarof for this skin disease.
Reports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent; Adjusted Diluted EPS of $2.95, a Decrease of 19.4 Percent; These.
27.10.2023 - Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, met the primary endpoint across three dosing arms; the study established eblasakimab’s potential to deliver a monthly .
/PRNewswire/ UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious.
Results from OLYMPIA 1 provide further support for nemolizumab as a potential first-in-class prurigo nodularis treatment; in another study, a JAK inhibitor was beneficial in patients with PN.